Search
forLearn
5 / 801 resultslearn octapeptide-2
learn PTD-DBM
learn Ceramide A2
learn ACETYL TETRAPEPTIDE-2
Research
5 / 1000+ resultsresearch Co-expression of PADI isoforms during progenitor differentiation enables functional diversity
Different PADI isoforms help cells develop diverse functions.
research 부챗말 Glucopyranosyldiacylglycerol의 탈모방지 효능
Padina arborescens and its component MOGG may help prevent hair loss through several actions, including blocking a hair loss-related enzyme.
research Successful Immunsuppression in Childhood Alopecia Areata
Immunosuppression therapy with methylprednisolone effectively treats childhood alopecia areata.
research A BRIEF STUDY ON ALOPECIA AREATA
Alopecia areata causes hair loss with varied treatment responses and frequent relapses.
research Diffuser Haarausfall und klinische Endokrinologie: Neue Erkenntnisse
Hormones significantly affect hair growth and loss, with potential for new treatments.
Community Join
5 / 1000+ resultscommunity Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community Pelage Recruiting Now for Phase 2
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.